BridgeBio Pharma stock heads into new acoramidis data

Published on 10/08/2026 at 02:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BridgeBio Pharma stock was at USD 66.73 on October 7, 2026, as HFSA prepares new acoramidis data. Q2 revenue rose 120.4 percent to USD 243.68 million.

BBIO, US10806X1028, Illustration mit AI erstellt.

BridgeBio Pharma (ISIN US10806X1028) was trading at USD 66.73 on Nasdaq on October 7, 2026 at 1:29 p.m. ET, down 0.34 percent from USD 66.96. The company is heading into a new clinical-data presentation for acoramidis, its commercial ATTR-CM medicine.

Acoramidis data arrive October 9

According to GlobeNewswire on October 6, BridgeBio will present one oral presentation, three rapid-fire oral presentations and six posters at the Heart Failure Society of America annual meeting in Phoenix. The meeting starts October 9, 2026, and the program includes comparative real-world data on acoramidis and tafamidis.

The presentation schedule gives investors a near-term clinical checkpoint rather than a new financial forecast. BridgeBio said the studies cover cardiovascular hospitalizations, mortality, kidney-function changes and longer-term cardiac outcomes for patients with transthyretin amyloid cardiomyopathy.

Revenue grew as losses persisted

BridgeBio reported USD 243.68 million in second-quarter 2026 revenue, up 120.4 percent from the year-earlier quarter, according to MarketBeat. The same report said quarterly EPS was negative USD 0.78 versus a consensus loss of USD 0.58, making the earnings profile a two-sided story.

The revenue comparison is the stronger operating signal, but the EPS miss shows that commercial expansion has not yet translated into quarterly profitability. The company reported USD 222.4 million in U.S. Attruby product revenue during the quarter, according to MarketBeat, linking the top-line increase to its lead commercial product.

Analyst targets remain above the stock

MarketBeat listed 20 Buy ratings, two Holds and one Sell, producing a Moderate Buy consensus and an average price target of USD 101.53. That target lies 52.1 percent above the October 7 Nasdaq price of USD 66.73, while the published range stretched from USD 80 to USD 157.

That valuation gap places the upcoming clinical presentations alongside execution risk. The October 7 quote stood USD 26.69 below the 52-week high of USD 93.42 and USD 13.98 above the 52-week low of USD 52.75, leaving the stock near the lower half of its annual range.

Stock trades below its yearly high

BridgeBio Pharma stock was trading at USD 66.73 on Nasdaq on October 7, 2026 at 1:29 p.m. ET. Its market capitalization was USD 13.1 billion and volume was 900,140 shares at that time.